BET-IN-16 (Comp I), a bromodomain and extra-terminal (BET) inhibitor, demonstrates anticancer activity by impeding the growth of prostate cancer cells. It exhibits potent inhibitory effects with half-maximal inhibitory concentration (IC50) values of 0.043 μM for LNCaP cells and 0.034 μM for 22Rv1 cells [1].

Menin-MLL Inhibitor 29 (Compound C1) is a Menin-MLL protein-protein interaction (PPI) inhibitor that demonstrates high affinity to Menin with a dissociation constant (K D) of 138 nM and impedes Menin's interaction with Menin-binding motif 1 (MBM1), as evidenced by an inhibition constant (IC 50) of 46 nM. Additionally, it exhibits anti-proliferative activity against HepG2 and Hep3B hepatoma cell lines with IC 50 values of 0.31 μM and 0.71 μM, respectively, and has been shown to inhibit tumor growth [1].

SMD-3040 is a potent and selective SMARCA2 PROTAC degrader (DC50: 12 nM), which consists of an SMARCA2/4 ligand, a linker, and a VHL ligand. It exhibits excellent degradation selectivity for the SMARCA2 protein over the SMARCA4 protein and has demonstrated robust tumor growth inhibition in xenograft models [1].

PROTAC BET Degrader-1 is a potent degrader of BET based on PROTAC.

(R)-UT-155 is a selective androgen receptor degrader (SARD) ligand.